BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

SEC Filings
Form 6-K
BIOLINERX LTD. filed this Form 6-K on 04/05/2017
Document Outline
Entire Document (323.5 KB)
Subdocument 1 - 6-K - FORM 6-K
Page 1 - For the month of April 2017
Page 2 - Item 8.01 Other Events.
Page 3 - N/A
Subdocument 2 - EX-1.1 - EXHIBIT 1.1
Page 1 - Exhibit 1.1
Page 2 - BIOLINERX LTD.
Page 3 - Firm ADSs Payment and Delivery
Page 4 - Schedule 1
Page 5 - Preliminary Prospectus
Page 6 - ADS Registration Statement
Page 7 - Underwriters Information
Page 8 - Material Adverse Effect
Page 9 - IFRS
Page 10 - Registration Rights of Third Parties
Page 11 - Corporate Power; Licenses; Consents
Page 12 - Insurance
Page 13 - OFAC
Page 14 - EMA
Page 15 - Sarbanes-Oxley Act
Page 16 - No Investment Company Status
Page 17 - taxes
Page 18 - ERISA Compliance
Page 19 - Investment Center
Page 20 - Israeli Securities Law
Page 21 - Federal Securities Laws
Page 22 - Free Writing Prospectuses
Page 23 - Delivery to the Underwriters of Prospectuses
Page 24 - Application of Net Proceeds
Page 25 - FINRA Clearance
Page 26 - Cold Comfort Letter
Page 27 - Secretary s Certificate
Page 28 - Delivery of Agreements before Signing
Page 29 - Procedure
Page 30 - Contribution
Page 31 - Default Not Exceeding 10% of Firm ADSs or Option ADSs
Page 32 - Underwriter
Page 33 - Expenses
Page 34 - Headings
Page 35 - Execution in Counterparts
Page 36 - Signature Page Follows
Page 37 - Schedule 1
Page 38 - SCHEDULE 1
Page 39 - SCHEDULE 2-A
Page 40 - SCHEDULE 2-B
Page 41 - SCHEDULE 3
Page 42 - EXHIBIT A
Page 43 - signature page follows
Page 44 - N/A
Subdocument 3 - EX-5.1 - EXHIBIT 5.1
Page 1 - Exhibit 5.1
Page 2 - N/A
Subdocument 4 - EX-5.2 - EXHIBIT 5.2
Page 1 - Exhibit 5.2
Page 2 - N/A
Subdocument 5 - EX-99.1 - EXHIBIT 99.1
Page 1 - Exhibit 99.1
Page 2 - www.biolinerx.com
Page 3 - tsipihai5@gmail.com


Interview with Philip Serlin, CEO
December 2016